Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China.
Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Belgium.
J Glob Health. 2024 Oct 11;14:04165. doi: 10.7189/jogh.14.04165.
Acute respiratory infection (ARI) poses a significant public health challenge worldwide, particularly among older adults. Understanding the cost of ARI management is important for optimising intervention strategy. We aimed to estimate the management cost of ARI in older adults in China.
We searched three English databases (MEDLINE, Embase, and Web of Science) and four Chinese databases (Chinese National Knowledge Infrastructure, Wanfang, SinoMed, and VIP) to identify studies published between 1 January 1995 and 27 February 2023 on the cost of ARI management in older adults in China. We pooled up age group and category-specific costs across individual studies by calculating median and interquartile range (IQR). All cost results were converted and inflated to USD in 2021.
We included 99 studies, of which 50 were determined as high quality. In those aged >60 years, the median total cost of ARI, including direct medical, direct non-medical, and indirect cost, was USD 3263 (IQR = 2676-3786) in the inpatient setting and USD 104 (IQR = 80-129) in the outpatient setting. For both inpatient and outpatient settings, direct medical costs accounted for most of the costs (69.3% and 54.8%, respectively). There was an increasing trend over age in the median direct medical cost in the inpatient setting, ranging from USD 1517 (IQR = 1114-2017) in those aged ≥50 years to USD 3493 (IQR = 2608-4378) in those aged ≥80 years.
Our study fills the knowledge gap on the cost of ARI and suggests that the overall cost of ARI is substantial among older adults in China. Cost data stratified by region, pathogen, and presence of comorbidities are warranted to help further identify subpopulations with higher ARI management costs.
PROSPERO CRD42023485669.
急性呼吸道感染(ARI)是全球范围内一个重大的公共卫生挑战,尤其在老年人中更为突出。了解 ARI 管理的成本对于优化干预策略至关重要。本研究旨在评估中国老年人 ARI 管理的成本。
我们检索了 3 个英文数据库(MEDLINE、Embase 和 Web of Science)和 4 个中文数据库(中国知网、万方、中国生物医学文献服务系统和维普),以确定 1995 年 1 月 1 日至 2023 年 2 月 27 日期间在中国发表的有关老年人 ARI 管理成本的研究。我们通过计算中位数和四分位距(IQR),对每个研究中的特定年龄组和类别成本进行汇总。所有成本结果均转换并换算为 2021 年的美元。
我们纳入了 99 项研究,其中 50 项被确定为高质量研究。在 60 岁以上的人群中,ARI 的总住院费用(包括直接医疗、直接非医疗和间接费用)为 3263 美元(IQR=2676-3786),门诊费用为 104 美元(IQR=80-129)。在住院和门诊环境下,直接医疗费用均占总费用的大部分(分别为 69.3%和 54.8%)。随着年龄的增长,住院环境下直接医疗费用的中位数呈上升趋势,从 50 岁以上人群的 1517 美元(IQR=1114-2017)到 80 岁以上人群的 3493 美元(IQR=2608-4378)。
本研究填补了中国 ARI 成本的知识空白,表明中国老年人 ARI 的总体成本相当高。需要按地区、病原体和合并症分层的成本数据,以帮助进一步确定 ARI 管理成本较高的亚人群。
PROSPERO CRD42023485669。